Replies to post #8729 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Thanks for your observations on Orencia. The $257M logged by BMY in 4Q11 was +10% QoQ as well as +25% YoY, which is indeed an impressive growth rate for a drug that has been on the market for several years. FDA approval of the subcutaneous formulation in Jul 2011 (#msg-65720598) is contributing to the growth rate.

All told, Orencia is doing pretty well for a drug that some analysts had dismissed as an also-ran. It’s the clear leader in RA among non-TNF-a biologics, easily outselling Rituxan and Actemra. Regards, Dew

[DewDiligence]

Orencia is now a blockbuster, selling at an annualized rate of $1.2B in 2Q12:

http://ih.advfn.com/p.php?pid=nmona&article=53586761

Sales grew 27% YoY, helped by the approval of the sub-q formulation in Jul 2011.

All told, not bad for a drug that some analysts had dismissed as an also-ran. It’s the clear leader in RA among non-TNF-a biologics, easily outselling Rituxan and Actemra.